|
CN102282155B
(zh)
|
2008-12-02 |
2017-06-09 |
日本波涛生命科学公司 |
磷原子修饰的核酸的合成方法
|
|
RU2612521C2
(ru)
|
2009-07-06 |
2017-03-09 |
Онтории, Инк. |
Новые пролекарства нуклеиновых кислот и способы их применения
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
CN103796657B
(zh)
|
2011-07-19 |
2017-07-11 |
波涛生命科学有限公司 |
合成官能化核酸的方法
|
|
KR102213609B1
(ko)
|
2012-07-13 |
2021-02-08 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
PL2872485T3
(pl)
|
2012-07-13 |
2021-05-31 |
Wave Life Sciences Ltd. |
Asymetryczna grupa pomocnicza
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
EP3234134B1
(en)
|
2014-12-17 |
2020-05-27 |
ProQR Therapeutics II B.V. |
Targeted rna editing
|
|
IL320434A
(en)
|
2015-07-22 |
2025-06-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods
|
|
IL295755A
(en)
*
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
CN108779132B
(zh)
|
2016-03-13 |
2022-04-15 |
波涛生命科学有限公司 |
用于亚磷酰胺和寡核苷酸合成的组合物和方法
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
EP3452596A4
(en)
|
2016-05-04 |
2020-03-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
JP2019520339A
(ja)
|
2016-06-03 |
2019-07-18 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド、その組成物および方法
|
|
WO2017220751A1
(en)
|
2016-06-22 |
2017-12-28 |
Proqr Therapeutics Ii B.V. |
Single-stranded rna-editing oligonucleotides
|
|
CN110352244B
(zh)
|
2016-09-01 |
2023-03-21 |
ProQR治疗上市公司Ⅱ |
化学修饰的编辑rna的单链寡核苷酸
|
|
US11873316B2
(en)
|
2016-11-23 |
2024-01-16 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
KR102810425B1
(ko)
|
2016-12-19 |
2025-05-21 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
PT3554552T
(pt)
|
2016-12-19 |
2022-10-03 |
Sarepta Therapeutics Inc |
Conjugados de oligómero de skipping de exão para distrofia muscular
|
|
KR20240006023A
(ko)
|
2016-12-19 |
2024-01-12 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
CA3065523A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
JP2020522510A
(ja)
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EP3664816A4
(en)
|
2017-08-08 |
2021-05-19 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
|
|
CA3072110A1
(en)
|
2017-09-18 |
2019-03-21 |
Wave Life Sciences Ltd. |
Technologies for oligonucleotide preparation
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
MX2020003130A
(es)
*
|
2017-09-22 |
2020-09-25 |
Avidity Biosciences Inc |
Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos.
|
|
WO2019067979A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
WO2019067981A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
EP3687547A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
US11559527B2
(en)
|
2017-12-20 |
2023-01-24 |
Lunella Biotech, Inc. |
Targeting mitochondrial fission through mDIVI-1 derivatives
|
|
SG11202009877XA
(en)
|
2018-04-12 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
US12391942B2
(en)
|
2018-05-11 |
2025-08-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
CN120247995A
(zh)
*
|
2018-05-30 |
2025-07-04 |
诺华股份有限公司 |
脂质修饰的核酸化合物和方法
|
|
EP3806868A4
(en)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
SG11202100928QA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
IL318474A
(en)
|
2018-12-13 |
2025-03-01 |
Sarepta Therapeutics Inc |
Axon-skipping oligomer complexes for muscular dystrophy
|
|
AU2019403368A1
(en)
*
|
2018-12-20 |
2021-07-29 |
Aegis Therapeutics, Llc |
Compositions, devices, and methods for the treatment of overdose and reward-based disorders
|
|
CN109799216B
(zh)
*
|
2018-12-29 |
2021-11-12 |
佛山科学技术学院 |
一种基于吲哚箐绿纳米的荧光oct双模成像方法和装置
|
|
JPWO2020158636A1
(ja)
*
|
2019-01-29 |
2021-12-02 |
国立大学法人 東京大学 |
核酸等を細胞内へ導入する方法
|
|
JP2022525541A
(ja)
|
2019-03-20 |
2022-05-17 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド調製に有用な技術
|
|
CN109870583B
(zh)
*
|
2019-04-15 |
2020-03-06 |
德阳市人民医院 |
急性胰腺炎相关的代谢物及其应用
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
JP7186442B2
(ja)
*
|
2019-04-22 |
2022-12-09 |
国立研究開発法人産業技術総合研究所 |
新規スクアレン誘導体および抗炎症剤
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
AU2020279395B2
(en)
*
|
2019-05-22 |
2025-08-28 |
Biovie Inc. |
Formulations of terlipressin
|
|
US20220364086A1
(en)
|
2019-07-12 |
2022-11-17 |
Daiichi Sankyo Company, Limited |
ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA
|
|
CN110527698B
(zh)
*
|
2019-08-23 |
2021-10-01 |
温氏食品集团股份有限公司 |
一种利用小分子化合物提高基因组定点插入效率的方法
|
|
CN111063870B
(zh)
*
|
2019-11-27 |
2021-09-24 |
深圳先进技术研究院 |
纳米材料及其制备方法、电极和二次电池
|
|
CA3166370A1
(en)
*
|
2019-11-27 |
2021-06-03 |
Dtx Pharma, Inc. |
Compounds and methods for the treatment of duchenne muscular dystrophy
|
|
CN111012788B
(zh)
*
|
2019-12-12 |
2021-01-15 |
武汉职业技术学院 |
硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
|
|
CN111055603B
(zh)
*
|
2019-12-31 |
2021-11-05 |
安徽省粤隆印刷科技有限公司 |
一种防止残剩油墨过度乳化和形成残渣的包装盒印刷工艺
|
|
JP2023515862A
(ja)
*
|
2020-03-01 |
2023-04-14 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
CN111358955B
(zh)
*
|
2020-04-01 |
2023-05-02 |
重庆理工大学 |
一种用于治疗脂质代谢疾病的炎症靶向的宾达利纳米粒、制备方法及其应用
|
|
CN111249298B
(zh)
*
|
2020-04-08 |
2021-03-12 |
曲阜师范大学 |
一种含有马杜霉素和顺铂的抗癌药物组合物
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
IT202000012577A1
(it)
*
|
2020-05-27 |
2021-11-27 |
Univ Degli Studi Roma La Sapienza |
Composizione farmaceutica per l’inibizione chimica di tgs1 come trattamento terapeutico per le telomeropatie
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
CN111789859A
(zh)
*
|
2020-07-20 |
2020-10-20 |
中国人民解放军海军军医大学 |
地塞米松在制备预防或缓解水母蜇伤药物中的应用
|
|
AU2021354760A1
(en)
*
|
2020-09-30 |
2023-05-11 |
Biomarin Technologies B.V. |
Antisense oligonucleotides targeting the exon 51 of dystrophin gene
|
|
EP3978608A1
(en)
*
|
2020-10-05 |
2022-04-06 |
SQY Therapeutics |
Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
|
|
CN115216474B
(zh)
*
|
2021-04-15 |
2025-09-30 |
武汉大学 |
促进pd-l1外显子3跳跃的反义寡核苷酸及其应用
|
|
JP2024525608A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
CN113520995B
(zh)
*
|
2021-08-16 |
2023-03-10 |
海南鑫开源医药科技有限公司 |
一种离子敏感型眼用原位凝胶、其制备方法及应用
|
|
EP4401777A4
(en)
*
|
2021-09-16 |
2025-08-13 |
Dyne Therapeutics Inc |
DOSAGE OF MUSCLE-TARGETING COMPLEXES TO TREAT DYSTROPHINOPATHIES
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
WO2023055774A1
(en)
|
2021-09-30 |
2023-04-06 |
Sarepta Therapeutics, Inc. |
Antisense oligonucleotides having one or more abasic units
|
|
EP4479535A1
(en)
|
2022-02-14 |
2024-12-25 |
ProQR Therapeutics II B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
US20260027237A1
(en)
|
2022-07-15 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
JP2025524566A
(ja)
|
2022-07-15 |
2025-07-30 |
プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ |
Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用
|
|
JP2025533454A
(ja)
|
2022-09-21 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
WO2024110565A1
(en)
|
2022-11-24 |
2024-05-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
AU2023390632A1
(en)
|
2022-12-09 |
2025-07-10 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
WO2024175550A1
(en)
|
2023-02-20 |
2024-08-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
US12396981B2
(en)
|
2023-03-09 |
2025-08-26 |
William Shulman |
Methods of using DMT
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
EP4689110A1
(en)
|
2023-03-24 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
EP4688143A1
(en)
|
2023-03-27 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
TW202442246A
(zh)
|
2023-04-27 |
2024-11-01 |
美商薩羅塔治療公司 |
用於治療慢性腎病之反義寡聚物
|
|
TW202516003A
(zh)
|
2023-06-16 |
2025-04-16 |
荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ |
用於治療神經退化性疾病之反義寡核苷酸
|
|
WO2025015335A1
(en)
|
2023-07-13 |
2025-01-16 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
CN116754689A
(zh)
*
|
2023-07-27 |
2023-09-15 |
苏州和合医学检验有限公司 |
一种高效液相色谱串联质谱法检测5种药物的方法及应用
|
|
CN117099681B
(zh)
*
|
2023-08-28 |
2024-07-05 |
南京农业大学 |
一种利用紫杉醇加倍玉米单倍体的方法
|
|
WO2025051946A1
(en)
|
2023-09-07 |
2025-03-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2025085810A2
(en)
|
2023-10-18 |
2025-04-24 |
Sarepta Therapeutics, Inc. |
Antisense oligomers for treatment of centronuclear myopathies
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
WO2025104239A1
(en)
|
2023-11-16 |
2025-05-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025132708A1
(en)
|
2023-12-20 |
2025-06-26 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025213142A2
(en)
*
|
2024-04-05 |
2025-10-09 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
CN119015397B
(zh)
*
|
2024-08-20 |
2025-04-18 |
广州医科大学附属中医医院(广州市中医中药研究所、广州市中医医院、广州中医药大学附属广州中医医院、广州市针灸医院) |
一种抑制人前列腺癌细胞增殖的白僵菌素组合物及其制备方法
|
|
WO2026050243A1
(en)
|
2024-08-26 |
2026-03-05 |
Korro Bio, Inc. |
Galnac conjugated oligonucleotides for rna editing
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|